89bio, Inc.
NASDAQ•ETNB
CEO: Mr. Rohan Palekar
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2019-11-11
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Contact Information
Market Cap
$2.20B
P/E (TTM)
-7.8
24.5
Dividend Yield
--
52W High
$15.06
52W Low
$4.16
52W Range
Rank70Top 99.2%
1.1
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data